Hemostatic Disorders
Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS.
Subtype terms (11)
More specific conditions that are subtypes of Hemostatic Disorders in the MeSH hierarchy.
- Cryoglobulinemia
9 drugs approved
- Ehlers-Danlos Syndrome
10 drugs (7 approved, 3 experimental)
- Hemangioma, Cavernous
- IgA Vasculitis
24 drugs (21 approved, 3 experimental)
- Multiple Myeloma
992 drugs (335 approved, 657 experimental)
- Pseudoxanthoma Elasticum
8 drugs (4 approved, 4 experimental)
- Purpura, Hyperglobulinemic
- Scurvy
2 drugs (1 approved, 1 experimental)
- Shwartzman Phenomenon
- Telangiectasia, Hereditary Hemorrhagic
19 drugs (15 approved, 4 experimental)
- Waldenstrom Macroglobulinemia
181 drugs (98 approved, 83 experimental)
Drugs by status
Phase 4 trials (1)
Phase 2 trials (2)
Phase 1 trials (2)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (28)
- CSL Behring
- Novo Nordisk
- Harvard University
- Florida International University
- NHS Lothian
- University of Edinburgh
- University of Florida
- University of Iowa
- University of Ottawa
- Wake Forest University
- University of Zurich
- Capital Medical University
- Dalian Medical University
- University of Chicago
- University of Copenhagen
- University of Turku
- Zhejiang University
- Jean Monnet University
- Adolphe Rothschild Ophtalmologic Foundation
- University of Toulouse
- University of Sao Paulo
- Mountain States Regional Hemophilia Center, Aurora, Columbia
- Department of Health and Human Services
- Canadian Hemophilia Society
- Government of Canada
- University of Helsinki
- Society for Obstetric Anesthesia and Perinatology
- Government of Nova Scotia
Organization Involved with Phase 3 Indications (52)
- Bayer
- Direction Centrale du Service de Santé des Armées
- National Heart, Lung, and Blood Institute (NHLBI)
- Unity Health Toronto
- University of Pittsburgh
- Federal University of Bahia
- University of Washington
- French Defence Health Service
- Johns Hopkins University
- McMaster University
- Medical University Innsbruck
- Monash University
- Rutgers University
- Thomas Jefferson University
- University of Oregon
- University of Toronto
- Wayne State University
- University of Vermont
- Austin Health
- University of Modena and Reggio Emilia
- Fire Brigade Of Paris
- Icahn School of Medicine at Mount Sinai
- Institut de Recherche Biomedicale des Armees
- University of Minnesota
- CHU Henri Mondor
- University of Lille
- Hebrew University
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Lyon
- Asahi Kasei Pharma
- +22 more
Organization Involved with Phase 2 Indications (17)
- Biomarin
- Catalyst Biosciences
- Instituto Bioclon
- Gilead Sciences
- Novartis
- Spark Therapeutics
- Entegrion, Inc.
- Aarhus University
- University of Pennsylvania
- University of Arizona
- Temple University
- Oriental Neurosurgery Evidence-Based-Study Team
- Yale University
- Assiut University
- Medical University of Vienna
- Ono Pharmaceuticals
- Celularity, Inc.
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (12)
- Abbott
- Cornell University
- Eastern Virginia Medical School
- Mary M. Gooley Hemophilia Center
- Seoul National University
- University of Pretoria
- University of Bern
- Institute of Liver and Biliary Sciences, India
- University of Strasbourg
- American College of Obstetricians and Gynecologists
- Centers for Disease Control and Prevention (CDC)
- Hospital Regional de Alta especialidad de Ixtapaluca